EVMN
NYSEEvommune, Inc.
Price
Key statistics
Insider activity
SEC EDGAR ↗Showing 20 recent filings. 11 other (grants, option exercises, gifts, tax withholding) are listed below but excluded from buy/sell flow.
| Insider | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|
Carver Kyle Chief Financial Officer | Buy (open market) | 1K | $13.26 | $13,260.00 | 2026-07-08 |
KIRSCH ARTHUR S Director | Buy (open market) | 10K | $13.30 | $133,000.00 | 2026-07-07 |
Drew Janice Suzann Chief of Dev. Operations | Option exercise | 3.84K | $3.84 | $14,741.76 | 2026-06-22 |
Drew Janice Suzann Chief of Dev. Operations | Option exercise | 16.16K | $2.99 | $48,321.39 | 2026-06-22 |
Drew Janice Suzann Chief of Dev. Operations | Sell (open market) | 20K | $22.63 | $452,600.00 | 2026-06-22 |
Drew Janice Suzann Chief of Dev. Operations | Option exercise | 3.84K | $0.00 | — | 2026-06-22 |
Drew Janice Suzann Chief of Dev. Operations | Option exercise | 16.16K | $0.00 | — | 2026-06-22 |
Patel Jeegar Pravinkumar Chief Scientific Officer | Option exercise | 1.49K | $3.84 | $5,713.92 | 2026-06-22 |
Patel Jeegar Pravinkumar Chief Scientific Officer | Sell (open market) | 1.49K | $22.50 | $33,480.00 | 2026-06-22 |
Patel Jeegar Pravinkumar Chief Scientific Officer | Option exercise | 1.49K | $0.00 | — | 2026-06-22 |
Pena Luis C. Director, President & CEO | Sell (open market) | 7.44K | $22.71 | $168,916.98 | 2026-06-22 |
MCGRAW BENJAMIN F III Director | Grant / award | 15.67K | $0.00 | — | 2026-06-02 |
KIRSCH ARTHUR S Director | Grant / award | 15.67K | $0.00 | — | 2026-06-02 |
Cohen David E Director | Sell (open market) | 5.46K | $20.21 | $110,265.76 | 2026-06-02 |
Cohen David E Director | Sell (open market) | 600 | $21.38 | $12,828.00 | 2026-06-02 |
Cohen David E Director | Grant / award | 15.67K | $0.00 | — | 2026-06-02 |
Patel Jeegar Pravinkumar Chief Scientific Officer | Option exercise | 13.51K | $3.84 | $51,886.08 | 2026-06-01 |
Patel Jeegar Pravinkumar Chief Scientific Officer | Sell (open market) | 16.69K | $22.74 | $379,462.38 | 2026-06-01 |
Patel Jeegar Pravinkumar Chief Scientific Officer | Option exercise | 13.51K | $0.00 | — | 2026-06-01 |
Pena Luis C. Director, President & CEO | Sell (open market) | 16.79K | $22.74 | $381,736.38 | 2026-06-01 |
Source: SEC EDGAR Forms 4/4A (CIK 2044725). Click an insider to open the original filing.
Social sentiment
Volume-weighted across live social sources
$EVMN ageing nicely. Shkreli nice contrarian indicator
$EVMN Phase 2 trial w/est Jul completion date NCT07150845: https://www.clinicaltrials.gov/study/NCT07150845 Trial Tracker: https://www.fdatracker.com/trial-tracker/
$EVMN Insider bought the dip: https://filingtracker.ai/filing/2044725/0001290976-26-000004
$EVMN
$EVMN Check out this great informative video on this company tons of info https://youtu.be/PRNOWUopqig?si=IHiaYq4otfM9aRJT
$EVMN well back down to my entry... lots of selling pressure breaking my chart setup
$CLDX got a bit of extra hype on the Russel 2000 and then the $EVMN crash. We are undisputed #1 for mast cell diseases right now and first to market if all goes well.
$EVMN Just loaded up!!
$EVMN averaged out, put it all in $CELH
$EVMN I just buy it at $13.5。
$EVMN Morgan Stanley lowered Evommune’s price target to $26 from $55, while maintaining an Overweight rating. HC Wainwright downgraded the stock to Neutral from Buy following a clinical trial failure. Analysts noted that the investment thesis is now weakened, as the stock is no longer supported by two previously credible mid-stage mechanisms, significantly reducing visibility on the pipeline.
$EVMN 8-10 is the buyzone.
Latest news
EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal
Top Midday Decliners
Evommune terminates oral drug’s development in CSU
Evommune Shares Slide After Phase 2b CSU Trial Misses Main Goal (EVMN)
Evommune's Trial of EVO756 Misses Primary Endpoint; Shares Tumble Pre-Bell
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
Companies Like Evommune (NYSE:EVMN) Are In A Position To Invest In Growth
Get insider-buy alerts
Free weekly digest of the most notable SEC insider purchases — plus early access to real-time alerts on your watchlist.